Foghorn Therapeutics announced it will not advance its FHD-909 drug and SMARCA2 degrader programs following clinical trial reviews, leading to a 40% workforce reduction. This decision caused the company's stock to fall nearly 31%. Pomerantz LLP is investigating whether Foghorn and its executives engaged in securities fraud or unlawful practices related to this news. The company plans to focus resources on its most promising proprietary programs moving forward.
Foghorn Therapeutics' recent workforce cut and program halt provide context for health sector trading activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 08, 2026 19:42 WIB: of 128 priced US health stocks, 34 rose and 88 fell. CRSP traded at USD 51.26 with a 2.08% decline and a typical hold time of 77 days, contrasting with ABEO's USD 5.18 price and 1.97% gain with a shorter hold time of 24 days. NVAX fell 1.96% to USD 11.00, with a typical hold time of 59 days and a majority sell order activity of 79%.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Seaport Global increased Shopify's price target from $175 to $180, reflecting an 8.3% upside from the current price of $166.16. Shopify's shares have surged 80% since May, pushing its market value above $205 billion. The rally is driven by a strategi...
Tesco reported earnings per share of $0.69, beating estimates of $0.64, despite revenue falling short at $44.60 billion versus $49.60 billion expected. The UK supermarket raised its full-year adjusted operating profit forecast to £3.15-3.30 billion, ...
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
